Radiation Added to Hormone Therapy Increases Survival for Men With Prostate Cancer

Publication
Article
OncologyONCOLOGY Vol 22 No 11
Volume 22
Issue 11

For men with locally advanced prostate cancer, the addition of radiation treatment to antiandrogen hormone therapy reduces the risk of dying of prostate cancer by 50% compared to those who have antiandrogen hormone treatment alone, according to a randomized study presented September 22, 2008, during the plenary session of the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston.

For men with locally advanced prostate cancer, the addition of radiation treatment to antiandrogen hormone therapy reduces the risk of dying of prostate cancer by 50% compared to those who have antiandrogen hormone treatment alone, according to a randomized study presented September 22, 2008, during the plenary session of the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston.

Key Finding

“This randomized trial is the first to show that men with locally advanced prostate cancer will survive substantially longer when radiation is added to their treatment plan,” said Anders Widmark, md, lead author of the study and a professor in radiation oncology at Umea University in Umea, Sweden. “I would encourage men with locally advanced prostate cancer to talk to their doctor to see if they would be a good candidate for radiation therapy in addition to hormone treatment.”

The study involved 880 patients with locally advanced prostate cancer who were randomly assigned to receive 3 months of intense hormone therapy (temporary castration) called total elimination of androgens in the body (total androgen blockade) followed by continuous antiandrogen therapy, allowing the testosterone to come back or the same hormonal treatment combined with radiation therapy between February 1996 to December 2002.

Findings show that 18% of patients who underwent hormone therapy alone died of prostate cancer, compared to 9% of those who had both hormone and radiation treatment. The quality of life at 4 years after treatment was similar between the two study groups, with the exception of decreased social function, which was observed in the patients who received the combined radiation-hormone treatment.

Recent Videos
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.